hotspot -WSS

hotspot

author：knowledge 2025-09-30 00:33:54 - browse：259

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Study on Amgen’s bispecific immunotherapy produces positive data

WSS

Smaller biotechs seek to piggyback on weight loss drug boom

Roche drug slashes death risk in early

Virtual Event: March of the Biosimilars

Stop the failed accountable care organization experiment

Health AI adoption puts security, privacy startups on investors' radar

STAT Summit: Meghan O’Rourke on making chronic illness visible

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

U.K. researchers warn about biases in medical devices, algorithms

Medicare details structure of new drug price negotiation program

Health AI adoption puts security, privacy startups on investors' radar

United colonoscopy coverage change 'may cost lives,' doctors say

Study on Amgen’s bispecific immunotherapy produces positive data

Walensky prepares to leave CDC — and Congress — behind

Methadone treatment changes are coming. Do they go far enough?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. researchers warn about biases in medical devices, algorithms

entertainment

STAT Readout Newsletter: Biotech news today

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Roivant's CEO is a star, but biotech's black hole persists

Colonoscopy prep: Liquid

Merck, Daiichi strike cancer drug pact worth up to $22 billion

entertainment

focus

hotspot

leisure time